Your browser doesn't support javascript.
loading
Clinical porcine islet xenotransplantation under comprehensive regulation.
Matsumoto, S; Tan, P; Baker, J; Durbin, K; Tomiya, M; Azuma, K; Doi, M; Elliott, R B.
Afiliação
  • Matsumoto S; Otsuka Pharmaceutical Factory, Naruto, Japan. Electronic address: matsumoto.shinichi@otsuka.jp.
  • Tan P; Living Cell Technologies, Auckland, New Zealand.
  • Baker J; Centre for Clinical Research and Effective Practice, Middlemore Hospital, Auckland, New Zealand.
  • Durbin K; Living Cell Technologies, Auckland, New Zealand.
  • Tomiya M; Otsuka Pharmaceutical Factory, Naruto, Japan.
  • Azuma K; Otsuka Pharmaceutical Factory, Naruto, Japan.
  • Doi M; Otsuka Pharmaceutical Factory, Naruto, Japan.
  • Elliott RB; Living Cell Technologies, Auckland, New Zealand.
Transplant Proc ; 46(6): 1992-5, 2014.
Article em En | MEDLINE | ID: mdl-25131091
BACKGROUND: Xenotransplantation with porcine islets is a promising approach to overcome the shortage of human donors. This is the first report of phase 1/2a xenotransplantation study of encapsulated neonatal porcine islets under the current framework of regulations for xenotransplantation in New Zealand. METHODS: Newborn piglets were anesthetized and bled, and the pancreata were removed with the use of sterile technique and processed. Encapsulated neonatal porcine islets were implanted with the use of laparoscopy into the peritoneal cavity of 14 patients with unstable type 1 diabetes without any immunosuppressive drugs. The patients received encapsulated islets of 5,000 (n = 4; group 1), 10,000 (n = 4; group 2), 15,000 (n = 4; group 3), or 20,000 (n = 2; group 4) islet equivalents per kg body weight. Outcome was determined from adverse event reports, HbA1c, total daily insulin dose, and frequency of unaware hypoglycemic events. To assess graft function, transplant estimated function (TEF) scores were calculated. Sufficient or marginal numbers of encapsulated neonatal porcine islets were transplanted into streptozotocin-induced diabetic B6 mice as an in vivo functional assay. RESULTS: There were 4 serious adverse events, of which 3 were considered to be possibly related to the procedure. Tests for porcine endogenous retrovirus DNA and RNA were all negative. The numbers of unaware hypoglycemia events were reduced after transplantation in all groups. Four of 14 patients attained HbA1c <7% compared with 1 at baseline. The average TEF scores were 0.17, 0.02, -0.01, and 0.08 in groups 1, 2, 3, and 4 respectively. The in vivo study demonstrated that a sufficient number of the transplanted group reversed diabetes with positive porcine C-peptide. CONCLUSIONS: Transplantation of encapsulated neonatal porcine islets was safe and was followed by a reduction in unaware hypoglycemia events in unstable type 1 diabetic patients. The mouse in vivo assessment data demonstrated certain graft function.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante Heterólogo / Transplante das Ilhotas Pancreáticas / Diabetes Mellitus Tipo 1 Tipo de estudo: Etiology_studies Limite: Animals / Female / Humans / Male / Middle aged País/Região como assunto: Oceania Idioma: En Revista: Transplant Proc Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante Heterólogo / Transplante das Ilhotas Pancreáticas / Diabetes Mellitus Tipo 1 Tipo de estudo: Etiology_studies Limite: Animals / Female / Humans / Male / Middle aged País/Região como assunto: Oceania Idioma: En Revista: Transplant Proc Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos